| Dr Katarzyna Barbara Iwan, MD | |
|
9925 Sw Nimbus Ave, #100, Beaverton, OR 97008-7591 | |
| (503) 535-8302 | |
| (855) 276-2456 |
| Full Name | Dr Katarzyna Barbara Iwan |
|---|---|
| Gender | Female |
| Speciality | Pain Management |
| Experience | 12 Years |
| Location | 9925 Sw Nimbus Ave, Beaverton, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467718908 | NPI | - | NPPES |
| 500753304 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | MD189597 (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Restore Interventional Spineand Sports Medicine Llc | 0244472181 | 3 |
News Archive
Research from McMaster University has found that bacteria in the gut impacts both intestinal and behavioural symptoms in patients suffering from irritable bowel syndrome (IBS), a finding which could lead to new microbiota-directed treatments.
A new study describes the structure of a crucial enzyme present in SARS-CoV-2.
When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment.
MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.
› Verified 6 days ago
| Entity Name | Restore Interventional Spine& Sports Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801139019 PECOS PAC ID: 0244472181 Enrollment ID: O20130806000571 |
News Archive
Research from McMaster University has found that bacteria in the gut impacts both intestinal and behavioural symptoms in patients suffering from irritable bowel syndrome (IBS), a finding which could lead to new microbiota-directed treatments.
A new study describes the structure of a crucial enzyme present in SARS-CoV-2.
When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment.
MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katarzyna Barbara Iwan, MD 9925 Sw Nimbus Ave, #100, Beaverton, OR 97008-7591 Ph: (503) 535-8302 | Dr Katarzyna Barbara Iwan, MD 9925 Sw Nimbus Ave, #100, Beaverton, OR 97008-7591 Ph: (503) 535-8302 |
News Archive
Research from McMaster University has found that bacteria in the gut impacts both intestinal and behavioural symptoms in patients suffering from irritable bowel syndrome (IBS), a finding which could lead to new microbiota-directed treatments.
A new study describes the structure of a crucial enzyme present in SARS-CoV-2.
When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment.
MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.
› Verified 6 days ago